Midatech Pharma PLC - drug delivery technology company - Reports Pretax loss of GBP17.9 million for the six months to the end of June compared to GBP5.3 million loss a year earlier, as revenue dropped to GBP8,000 from GBP230,000. Research and development costs were higher in the half-year, at GBP4.0 million from GBP3.5 million a year earlier, with administrative costs rising to GBP2.9 million from GBP2.0 million. In addition, the company reported impairment of intangible assets of GBP11.6 million, related to the termination of further in-house development of MTD201, versus no such cost recorded a year before.
Current stock price: 30.70 pence
Year-to-date change: down 49%
By Evelina Grecenko; firstname.lastname@example.org
Copyright 2020 Alliance News Limited. All Rights Reserved.